| 摘要 |
1,167,605. 5 - Halocytosine - 1 - nucleosides. UPJOHN CO. 27 Jan., 1967 [24 Feb., 1966], No. 4195/67. Heading C2C. 5-Halocytosine-1-nucleosides of the general formula wherein " Halogen " has an atomic weight between 35 and 131, Y is any glycosido group and -NR 1 R 2 is a substituted or unsubstituted amino group, are prepared by reaction of a cytosine-1-nucleoside with an N-halo cyclic imide in the presence of an inert solvent medium. 1 - D - Arabinofuranosyl - 4 - amino - 5 - halo- 2-(1H)-pyrimidones of the general formula wherein R 1 and R 2 are each a hydrogen atom or a C 1-8 alkyl, C 4-8 cycloalkyl, oxa- or C-azamonoheterocyclic, oxa- or C-aza-monoheterocyclic C 1-8 alkyl, C 6-10 aryl or C 7 _ 13 aralkyl group, or R 1 and R 2 , together with the nitrogen atom to which they are attached, form a saturated heterocyclic amino group -NZ of from 3 to 7 ring members, Z having a maximum total of 10 carbon atoms, one ring member being selected from carbon, nitrogen or oxygen so that Z is alkylene, oxa-alkylene, or azaalkylene, and acid addition salts thereof are novel compounds and are prepared by the above method, followed optionally by salification. Cytosine-1-nucleosides and acid addition salts thereof are prepared by reaction of a 1-(O- acetyl glycosyl)-4-thiouracil with a suitable amine, followed optionally by salification. 1 - (2,3,5 - Tri - 0 - acetyl - # - D - arabinofuranosyl)-4-thiouracil is prepared by reaction of the corresponding uracil compound with phosphorus pentasulphide. Pharmaceutical compositions having antiviral and antitumour cell activity comprise, as active ingredient, a l-D-arabinofuranosyl-4- amino-5-halo-2-(lH)- pyrimidone of the second general formula above or an acid addition salt thereof, together with a pharmaceutically acceptable carrier, and may be administered orally, rectally or parenterally.
|
